BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

AFFYMAX, INC. — Lobbying — Receipts Report

LD-2 disclosure · 1st Quarter - Termination

AFFYMAX, INC.

via SQUIRE PATTON BOGGS

1st Quarter (Jan 1 - Mar 31) · 2013Posted Apr 20, 2013Filing document ↗LDA record ↗

Income$50Kfee reported

Client

Name: AFFYMAX, INC.
Description: Pharmaceuticals
Location: California · United States of America

Registrant

Firm: SQUIRE PATTON BOGGS
Description: Law Firm
Location: WASHINGTON, District of Columbia, United States of America

Lobbying activities

2 issues

Health Issues
Issues related to dialysis medication; End Stage Renal Disease (ESRD) payment issues, H.R. 8, American Taxpayer Relief Act of 2012
LobbyistsKATHLEEN LESTER · JOHN JONAS · ERIC RASMUSSEN · HEIDE BAJNRAUH
Covered position (ERIC RASMUSSEN): SenCrapoLA04-07andDepPresSec03-02LegIntenHatch2000
Covered position (HEIDE BAJNRAUH): SenatorMcCainIntern94-96;LSA96-97
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
Issues related to dialysis medication; End Stage Renal Disease (ESRD) payment issues; H.R. 8, American Taxpayer Relief Act of 2012
LobbyistsKATHLEEN LESTER · JOHN JONAS · ERIC RASMUSSEN · HEIDE BAJNRAUH
Covered position (ERIC RASMUSSEN): SenCrapoLA04-07andDepPresSec03-02LegIntenHatch2000
Covered position (HEIDE BAJNRAUH): SenatorMcCainIntern94-96;LSA96-97
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.